288 related articles for article (PubMed ID: 25054744)
1. Onychomycosis: clinical, mycological and in vitro susceptibility testing of isolates of Trichophyton rubrum.
Azambuja CV; Pimmel LA; Klafke GB; Xavier MO
An Bras Dermatol; 2014; 89(4):581-6. PubMed ID: 25054744
[TBL] [Abstract][Full Text] [Related]
2. In vitro antifungal susceptibility patterns of dermatophyte strains causing tinea unguium.
Sarifakioglu E; Seçkin D; Demirbilek M; Can F
Clin Exp Dermatol; 2007 Nov; 32(6):675-9. PubMed ID: 17714532
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of susceptibility of Trichophyton mentagrophytes and Trichophyton rubrum clinical isolates to antifungal drugs using a modified CLSI microdilution method (M38-A).
Barros MEDS; Santos DA; Hamdan JS
J Med Microbiol; 2007 Apr; 56(Pt 4):514-518. PubMed ID: 17374893
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of fluconazole, itraconazole, voriconazole and terbinafine against fungi causing onychomycosis.
Bueno JG; Martinez C; Zapata B; Sanclemente G; Gallego M; Mesa AC
Clin Exp Dermatol; 2010 Aug; 35(6):658-63. PubMed ID: 19874354
[TBL] [Abstract][Full Text] [Related]
5. In vitro antifungal oral drug and drug-combination activity against onychomycosis causative dermatophytes.
Santos DA; Hamdan JS
Med Mycol; 2006 Jun; 44(4):357-62. PubMed ID: 16772230
[TBL] [Abstract][Full Text] [Related]
6. Antifungal susceptibilities and genetic relatedness of serial Trichophyton rubrum isolates from patients with onychomycosis of the toenail.
Bradley MC; Leidich S; Isham N; Elewski BE; Ghannoum MA
Mycoses; 1999; 42 Suppl 2():105-10. PubMed ID: 10865915
[TBL] [Abstract][Full Text] [Related]
7. Combinatorial effect of fluconazole, itraconazole, and terbinafine with different culture extracts of Candida parapsilosis and Trichophyton spp. against Trichophyton rubrum.
Lemes TH; Nascentes JAS; Regasini LO; Siqueira JPZ; Maschio-Lima T; Pattini VC; Ribeiro MD; de Almeida BG; de Almeida MTG
Int Microbiol; 2024 Jun; 27(3):899-905. PubMed ID: 37875749
[TBL] [Abstract][Full Text] [Related]
8. In vitro susceptibility testing of ciclopirox, terbinafine, ketoconazole and itraconazole against dermatophytes and nondermatophytes, and in vitro evaluation of combination antifungal activity.
Gupta AK; Kohli Y
Br J Dermatol; 2003 Aug; 149(2):296-305. PubMed ID: 12932235
[TBL] [Abstract][Full Text] [Related]
9. Prevalence and epidemiology of tinea pedis and toenail onychomycosis and antifungal susceptibility of the causative agents in patients with type 2 diabetes in Turkey.
Oz Y; Qoraan I; Oz A; Balta I
Int J Dermatol; 2017 Jan; 56(1):68-74. PubMed ID: 27667305
[TBL] [Abstract][Full Text] [Related]
10. Pharmacoeconomic analysis of ciclopirox nail lacquer solution 8% and the new oral antifungal agents used to treat dermatophyte toe onychomycosis in the United States.
Gupta AK
J Am Acad Dermatol; 2000 Oct; 43(4 Suppl):S81-95. PubMed ID: 11051137
[TBL] [Abstract][Full Text] [Related]
11. Sporicidal effect of amorolfine and other antimycotics used in the therapy of fungal nail infections.
Seidl HP; Jäckel A; Müller J; Schaller M; Borelli C; Polak A
Mycoses; 2015 Oct; 58(10):610-9. PubMed ID: 26334024
[TBL] [Abstract][Full Text] [Related]
12. Comparison of in vitro antifungal activities of efinaconazole and currently available antifungal agents against a variety of pathogenic fungi associated with onychomycosis.
Jo Siu WJ; Tatsumi Y; Senda H; Pillai R; Nakamura T; Sone D; Fothergill A
Antimicrob Agents Chemother; 2013 Apr; 57(4):1610-6. PubMed ID: 23318803
[TBL] [Abstract][Full Text] [Related]
13.
Singh SK; Patwa DK; Tilak R; Das A; Singh TB
Indian J Dermatol Venereol Leprol; 2019; 85(4):388-392. PubMed ID: 30950409
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the antifungal efficacy of terbinafine hydrochloride and ciclopirox olamine containing formulations against the dermatophyte Trichophyton rubrum in an infected nail plate model.
Täuber A; Müller-Goymann CC
Mol Pharm; 2014 Jul; 11(7):1991-6. PubMed ID: 24490976
[TBL] [Abstract][Full Text] [Related]
15. Activity of TDT 067 (terbinafine in Transfersome) against agents of onychomycosis, as determined by minimum inhibitory and fungicidal concentrations.
Ghannoum M; Isham N; Herbert J; Henry W; Yurdakul S
J Clin Microbiol; 2011 May; 49(5):1716-20. PubMed ID: 21411586
[TBL] [Abstract][Full Text] [Related]
16. Molecular typing and antifungal susceptibility of Trichophyton rubrum isolates from patients with onychomycosis pre- and post-treatment.
de Assis Santos D; de Carvalho Araújo RA; Kohler LM; Machado-Pinto J; Hamdan JS; Cisalpino PS
Int J Antimicrob Agents; 2007 May; 29(5):563-9. PubMed ID: 17331707
[TBL] [Abstract][Full Text] [Related]
17. In vitro antifungal susceptibility testing of fungi in patients with onychomycosis.
Abu El-Hamd M; Abd Elhameed MI; Shalaby MFM; Saleh R
Dermatol Ther; 2020 May; 33(3):e13429. PubMed ID: 32304603
[TBL] [Abstract][Full Text] [Related]
18. Action mechanisms of modern antifungal agents and resulting problems in the management of onychomycosis.
Seebacher C
Mycoses; 2003 Dec; 46(11-12):506-10. PubMed ID: 14641625
[TBL] [Abstract][Full Text] [Related]
19. Determination of minimum inhibitory concentrations of itraconazole, terbinafine and ketoconazole against dermatophyte species by broth microdilution method.
Bhatia VK; Sharma PC
Indian J Med Microbiol; 2015; 33(4):533-7. PubMed ID: 26470960
[TBL] [Abstract][Full Text] [Related]
20. Characterization of Antifungal Activity and Nail Penetration of ME1111, a New Antifungal Agent for Topical Treatment of Onychomycosis.
Tabata Y; Takei-Masuda N; Kubota N; Takahata S; Ohyama M; Kaneda K; Iida M; Maebashi K
Antimicrob Agents Chemother; 2016 Feb; 60(2):1035-9. PubMed ID: 26643333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
